AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03070717 — intervention group
Intervention type: PROCEDURE
Intervention: Observation & Diagnosis
Description: SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
Study NCT01491074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab 280 mg
Description: Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
Study NCT01491074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% 100 ml
Description: Placebo
Study NCT04795310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment.
Study NCT04795310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser
Description: PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD).~IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment.
Study NCT00671008 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT00671008 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT02465996 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: pCLE examination
Description: All FD patients received pCLE examination.
Study NCT02465996 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Puyuanhewei
Description: FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
Study NCT04498195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increased exercise and physical activity
Description: Participants were encouraged to increase physical activity for 12-week study duration and wear an activity tracker for a minimum of 12 hours a day.
Study NCT03992534 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LACTIN-V
Description: Vaginal supplementation with L. crispatus CTV-05.
Study NCT02468102 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily \[bid\] for 3 weeks, then 15 mg or 20 mg once daily \[od\], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation \[SPAF\]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban \[od\], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban \[od\] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets \[bid\]).
Study NCT02468102 — intervention group
Intervention type: DRUG
Intervention: Standard of care drugs
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Study NCT04615182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transplant
Description: To enable continued clinical access to DCD heart transplantation in the U.S. and to continue to collect additional data on the performance of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
Study NCT04459286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide and atazanavir/ritonavir
Description: 1000 mg nitazoxanide tablets twice daily and 300/100 mg atazanavir/ritonavir tablets once daily with meal
Study NCT04459286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
Study NCT04459286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: SOC will be as determined by the clinical team at the treatment centres in line with the current National Interim Guidelines for Clinical Management of COVID-19
Study NCT02993939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Ultrasound guided single shot block above the clavicle
Study NCT02993939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular-suprascapular block
Description: Combined block of nerves far away from phrenic nerve
Study NCT03548805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ologen® Collagen Matrix
Description: Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
Study NCT03548805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with low dose mitomycin C
Description: Trabeculectomy with low dose MMC
Study NCT00781066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled cord traction
Description: 1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~2. Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~3. Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~4. With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~5. If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~   * Gently hold the cord and wait until the uterus is well contracted again;~  * With the next contraction, repeat CCT with counter-pressure.
Study NCT00781066 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No controlled cord traction
Description: 1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~2. No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~3. After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity.
Study NCT01370005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose
Study NCT01370005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose once daily
Study NCT01370005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose
Study NCT01370005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose once daily
Study NCT01370005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose
Study NCT01370005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose
Study NCT03285841 — intervention group
Intervention type: DEVICE
Intervention: OCT-AFI
Description: Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
Study NCT03808337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy/SBRT
Description: Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
Study NCT03808337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Therapy/Standard of Care
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
Study NCT03808337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Therapy/Standard of Care
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
Study NCT05686772 — intervention group
Intervention type: DRUG
Intervention: Dopamine partial agonists
Description: Use of antipsychotics (i.e., dopamine partial agonists vs dopamine antagonists)
Study NCT05686772 — intervention group
Intervention type: OTHER
Intervention: Psychiatric comorbidities
Description: Mainly substance use disorders and personality disorders
Study NCT05686772 — intervention group
Intervention type: OTHER
Intervention: Sex
Description: Biological sex at birth
Study NCT05686772 — intervention group
Intervention type: OTHER
Intervention: Gender
Description: Current gender identity
Study NCT05686772 — intervention group
Intervention type: OTHER
Intervention: Socioeconomic status
Description: Including main source of income, employment status, homelessness
Study NCT05686772 — intervention group
Intervention type: OTHER
Intervention: Gambling history
Description: History of gambling (i.e., recreational or problematic) prior to admission in the clinics
Study NCT01743794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
Study NCT01743794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution 0.9%
Description: wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
Study NCT02688465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Study NCT03454464 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional
Description: Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
Study NCT03454464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: central neck dissection first
Description: central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
Study NCT02553811 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: accuracy diagnostic
Description: effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
Study NCT02480816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral water
Description: Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
Study NCT02480816 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral water
Description: Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
Study NCT02630524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Behavioral Lifestyle Intervention Device: Telecoach
Description: Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
Study NCT02630524 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Behavioral Lifestyle Intervention Device: Telecoach
Description: Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
Study NCT04636346 — intervention group
Intervention type: BEHAVIORAL
Intervention: Acceptance and Commitment Therapy
Description: Seven group sessions
Study NCT04636346 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
Study NCT00061113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine + outpatient cognitive behavioral therapy
Description: single fixed morning dose 20 mg X 15 weeks
Study NCT00061113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20mg, QD x 16 weeks
Study NCT00061113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + CBT
Description: single fixed morning dose X 16 weeks
Study NCT04197011 — intervention group
Intervention type: DEVICE
Intervention: prosthetic device
Description: Individuals with TFA will use a combination of prosthetic devices.
Study NCT03746184 — intervention group
Intervention type: OTHER
Intervention: Treatment course
Description: Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
Study NCT03915184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zevor-cel
Description: A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
Study NCT00189592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArthroCare TOPAZ™ MicroDebrider™ using Coblation
Description: Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
Study NCT00189592 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Fasciotomy
Description: Standard surgical fasciotomy using an incision to treat the plantar fascia.
Study NCT03183713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
Study NCT02322814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
Study NCT02322814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Study NCT02322814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Study NCT03183713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Therapy
Description: Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
Study NCT04443062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: PSMA radioligand therapy
Study NCT02322814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
Study NCT02322814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
Study NCT02322814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Study NCT00280657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valette
Description: 1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
Study NCT00280657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diane
Description: 1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
Study NCT00280657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
Study NCT02034253 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
Study NCT03928002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D Flow magnetic resonance imagery
Description: acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information
Study NCT03928002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheterization
Description: pulmonary vascular resistance calculation ;
Study NCT03352843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
Study NCT02484079 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy
Study NCT05341102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.
Study NCT05341102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT01164228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV